{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T05:00:02Z","timestamp":1785128402749,"version":"3.55.0"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      In treatment-refractory schizophrenia (TRS), a predose plasma concentration of 0.35\u2009mg\u2009L\n                      <jats:sup>\u22121<\/jats:sup>\n                      is suggested to ensure an adequate trial of clozapine, but the target range may differ between smokers and nonsmokers.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method:<\/jats:title>\n                    <jats:p>We studied data from a clozapine therapeutic drug monitoring service, 1993\u20132017, with respect to age, sex, smoking status, clozapine dose, estimated clozapine treatment duration, plasma clozapine and norclozapine concentrations, and reason for the request.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      There were 35,147 and 88,279 samples from 8882 women and 20,378 men, respectively, for which reasons for the request were specified (26,572 samples, 2 reasons; 6421, 3 or more reasons). More samples were sent for analysis due to suspected adverse drug reactions (ADRs) from women (5.3 vs 4.7%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&lt;\u20090.001). The median minimum duration of clozapine treatment before the suspected reaction was 156\u2009days shorter in nonsmokers than smokers of either sex (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&lt;\u20090.001) and shorter in female than male nonsmokers (189 vs 334\u2009d;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&lt;\u20090.01). The differences in median plasma clozapine concentrations between suspected ADR (1869\/4149 samples from women\/men, respectively), and control (10,627\/25,848 samples from women\/men, respectively) groups were small, averaging 0.03\u2009mg\u2009L\n                      <jats:sup>\u22121<\/jats:sup>\n                      (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&lt;\u20090.01), but the median plasma clozapine in the ADR and baseline groups was 0.15\u2009mg\u2009L\n                      <jats:sup>\u22121<\/jats:sup>\n                      lower in smokers than nonsmokers (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Implications:<\/jats:title>\n                    <jats:p>\n                      The target ranges associated with response to clozapine and minimal ADRs in TRS may be 0.35\u20130.45 and 0.50\u20130.60\u2009mg\u2009L\n                      <jats:sup>\u22121<\/jats:sup>\n                      in smokers and in nonsmokers, respectively. ADRs may occur earlier in treatment in nonsmokers, particularly in women, who in general have higher predose plasma clozapine concentrations than men.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/jcp.0000000000002007","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T15:06:08Z","timestamp":1744124768000},"page":"336-344","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Plasma Clozapine in Treatment Refractory Schizophrenia"],"prefix":"10.1097","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1081-7463","authenticated-orcid":false,"given":"Robert James","family":"Flanagan","sequence":"first","affiliation":[{"name":"Precision Medicine, Networked Services, Bessemer Wing, King's College Hospital NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen John","family":"Obee","sequence":"additional","affiliation":[{"name":"Precision Medicine, Networked Services, Bessemer Wing, King's College Hospital NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice Hyun Min","family":"Kim","sequence":"additional","affiliation":[{"name":"Biostatistics Group, Dean's Department, University of Otago"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Every-Palmer","sequence":"additional","affiliation":[{"name":"Department of Psychological Medicine, University of Otago, Wellington, Mein Street, Wellington, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula Liren Valbuena","family":"Sanchez","sequence":"additional","affiliation":[{"name":"Division of Psychiatry, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Evans","sequence":"additional","affiliation":[{"name":"Division of Psychiatry, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Rogers","sequence":"additional","affiliation":[{"name":"Division of Psychiatry, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Reeves","sequence":"additional","affiliation":[{"name":"Division of Psychiatry, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,4,9]]},"reference":[{"key":"bib1-20260219","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1007\/s00228-014-1772-0","article-title":"Clozapine serum concentrations in dopamimetic psychosis in Parkinson's disease and related disorders","volume":"70","author":"Lutz","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"key":"bib2-20260219","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/YIC.0b013e32835ac9da","article-title":"Clinical predictors of serum clozapine levels in patients with treatment-resistant schizophrenia","volume":"28","author":"Rajkumar","year":"2012","journal-title":"Int Clin Psychopharmacol"},{"key":"bib3-20260219","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/acps.13228","article-title":"Impact of smoking behavior on clozapine blood levels - a systematic review and meta-analysis","volume":"142","author":"Wagner","year":"2020","journal-title":"Acta Psychiatr Scand"},{"key":"bib4-20260219","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/JCP.0000000000001909","article-title":"Plasma clozapine and N-desmethylclozapine (norclozapine) concentrations and the clozapine:norclozapine ratio: effect of dose, sex, and cigarette smoking","volume":"44","author":"Flanagan","year":"2024","journal-title":"J Clin Psychopharmacol"},{"key":"bib5-20260219","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/JCP.0000000000001736","article-title":"Assessing adherence to clozapine: practical considerations","volume":"43","author":"Flanagan","year":"2023","journal-title":"J Clin Psychopharmacol"},{"key":"bib6-20260219","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1055\/s-0043-117891","article-title":"A critical commentary on the 2017 AGNP consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology","volume":"51","author":"de Leon","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"bib7-20260219","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1159\/000507638","article-title":"A rational use of clozapine based on adverse drug reactions, pharmacokinetics, and clinical pharmacopsychology","volume":"89","author":"de Leon","year":"2020","journal-title":"Psychother Psychosom"},{"key":"bib8-20260219","doi-asserted-by":"crossref","first-page":"817","DOI":"10.3390\/ph15070817","article-title":"Adverse drug reactions in relation to clozapine plasma levels: a systematic review","volume":"15","author":"Skokou","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"bib9-20260219","first-page":"1","article-title":"Therapeutic monitoring of plasma clozapine and N-desmethylclozapine (norclozapine): practical considerations","volume":"29","author":"Flanagan","year":"2023","journal-title":"Br J Psychiatry Adv"},{"key":"bib10-20260219","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/s-0043-116492","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"bib11-20260219","doi-asserted-by":"crossref","first-page":"68","DOI":"10.9740\/mhc.2015.03.068","article-title":"A review of the clinical utility of serum clozapine and norclozapine levels","volume":"5","author":"Ellison","year":"2015","journal-title":"Ment Hlth Clinician"},{"key":"bib12-20260219","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00213-012-2922-7","article-title":"Clozapine and therapeutic drug monitoring: is there sufficient evidence for an upper threshold?","volume":"225","author":"Remington","year":"2013","journal-title":"Psychopharmacology (Berl)"},{"key":"bib13-20260219","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1192\/bjp.2023.27","article-title":"Optimising plasma clozapine levels to improve treatment response: an individual patient data meta-analysis and receiver operating characteristic curve analysis","volume":"222","author":"Northwood","year":"2023","journal-title":"Br J Psychiatry"},{"key":"bib14-20260219","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/FTD.0b013e3181dad1fb","article-title":"Plasma clozapine, norclozapine, and the clozapine:norclozapine ratio in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1993\u20132007","volume":"32","author":"Couchman","year":"2010","journal-title":"Ther Drug Monit"},{"key":"bib15-20260219","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1097\/JCP.0000000000001762","article-title":"Effect of cigarette smoking on clozapine dose and on plasma clozapine and N-desmethylclozapine (norclozapine) concentrations in clinical practice","volume":"43","author":"Flanagan","year":"2023","journal-title":"J Clin Psychopharmacol"},{"key":"bib16-20260219","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/JCP.0000000000001653","article-title":"Clozapine: dose, sex, ethnicity, smoking habit, age, body weight, and plasma clozapine and N-desmethylclozapine (norclozapine) concentrations in clinical practice","volume":"43","author":"Flanagan","year":"2023","journal-title":"J Clin Psychopharmacol"},{"key":"bib18-20260219","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2023.115539","article-title":"Comprehensive dissection of prevalence rates, sex differences, and blood level-dependencies of clozapine-associated adverse drug reactions","volume":"330","author":"van der Horst","year":"2023","journal-title":"Psychiatry Res"},{"key":"bib19-20260219","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/bcp.15691","article-title":"A population pharmacokinetic model to guide clozapine dose selection, based on age, sex, ethnicity, body weight and smoking status","volume":"90","author":"Reeves","year":"2024","journal-title":"Br J Clin Pharmacol"},{"key":"bib20-20260219","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1080\/14740338.2024.2362796","article-title":"Overcoming clozapine's adverse events: a narrative review of systematic reviews and meta-analyses","volume":"23","author":"Tanzer","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"bib21-20260219","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nm.4274","article-title":"Nicotine reverses hypofrontality in animal models of addiction and schizophrenia","volume":"23","author":"Koukouli","year":"2017","journal-title":"Nat Med"},{"key":"bib22-20260219","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41537-024-00449-1","article-title":"Smoking affects symptom improvement in schizophrenia: a prospective longitudinal study of male patients with first-episode schizophrenia","volume":"10","author":"Mu","year":"2024","journal-title":"Schizophrenia (Heidelb)"},{"key":"bib23-20260219","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/j.1365-2125.2011.04023.x","article-title":"Effect of nicotine on cytochrome P450 1A2 activity","volume":"72","author":"Hukkanen","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"bib24-20260219","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3390\/jpm7040018","article-title":"Variation in CYP2A6 activity and personalized medicine","volume":"7","author":"Tanner","year":"2017","journal-title":"J Pers Med"},{"key":"bib25-20260219","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3390\/ph14060514","article-title":"Therapeutic drug monitoring of second- and third-generation antipsychotic drugs-influence of smoking behavior and inflammation on pharmacokinetics","volume":"14","author":"Moschny","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"bib26-20260219","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/YCO.0000000000000594","article-title":"Antipsychotics and the microbiota","volume":"33","author":"Chen","year":"2020","journal-title":"Curr Opin Psychiatry"},{"key":"bib27-20260219","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.trsl.2016.08.002","article-title":"Nicholson JK. Gut microbiome interactions with drug metabolism, efficacy, and toxicity","volume":"179","author":"Wilson","year":"2017","journal-title":"Transl Res"},{"key":"bib28-20260219","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/14740338.2022.2042251","article-title":"Does the gut microbiome mediate antipsychotic-induced metabolic side effects in schizophrenia?","volume":"21","author":"Vasileva","year":"2022","journal-title":"Expert Opin Drug Saf"},{"key":"bib29-20260219","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1001\/jamapsychiatry.2023.5371","article-title":"Associations of the gut microbiome with treatment resistance in schizophrenia","volume":"81","author":"Vasileva","year":"2024","journal-title":"JAMA Psychiatry"},{"key":"bib30-20260219","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1046\/j.1360-0443.2003.00497.x","article-title":"Stopping smoking can cause constipation","volume":"98","author":"Hajek","year":"2003","journal-title":"Addiction"},{"key":"bib31-20260219","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/01.jcp.0000106221.36344.4d","article-title":"Influence of dose, cigarette smoki, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients","volume":"24","author":"Rostami-Hodjegan","year":"2004","journal-title":"J Clin Psychopharmacol"},{"key":"bib32-20260219","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ebiom.2016.02.020","article-title":"Clozapine-treated patients have marked gastrointestinal hypomotility, the probable basis of life-threatening gastrointestinal complications: a cross sectional study","volume":"5","author":"Every-Palmer","year":"2016","journal-title":"EBioMedicine"},{"key":"bib33-20260219","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13293-020-00308-5","article-title":"Sex differences in pharmacokinetics predict adverse drug reactions in women","volume":"11","author":"Zucker","year":"2020","journal-title":"Biol Sex Differ"},{"key":"bib34-20260219","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1177\/2045125315591917","article-title":"Factors predicting use of laxatives in outpatients stabilized on clozapine","volume":"5","author":"Bailey","year":"2015","journal-title":"Ther Adv Psychopharmacol"},{"key":"bib35-20260219","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2019.112506","article-title":"A systematic review of sex-based differences in effectiveness and adverse effects of clozapine","volume":"280","author":"Alberich","year":"2019","journal-title":"Psychiatry Res"},{"key":"bib36-20260219","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1176\/appi.ajp.20230744","article-title":"High burden of ileus and pneumonia in clozapine-treated individuals with schizophrenia: a Finnish 25-year follow-up register study","volume":"181","author":"Partanen","year":"2024","journal-title":"Am J Psychiatry"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JCP.0000000000002007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T15:00:37Z","timestamp":1771513237000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/JCP.0000000000002007"}},"subtitle":["What Is the Target Range?"],"short-title":[],"issued":{"date-parts":[[2025,4,9]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0000000000002007","relation":{},"ISSN":["1533-712X","0271-0749"],"issn-type":[{"value":"1533-712X","type":"electronic"},{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,9]]}}}